{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.40","upperLimit":"49.50","value":"47.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"comment":"below the level of detection","groupId":"OG000","lowerLimit":"16.80","upperLimit":"47.00","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"description":"Time of Clast (Tlast) will be obtained from the Tlast parameter calculated by WinNonlin®. If there is no measurable concentration in the subject's PK profile, then Tlast will be missing for that participants. Tlast will be reported in units of h.","dispersionType":"Full Range","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in PAS population, defined as all participants who provide at least one post-dose PK plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Time of Clast (Tlast) of Panobinostat","type":"SECONDARY","unitOfMeasure":"Hours"}